Meeting
2018 Palliative and Supportive Care in Oncology Symposium
Switching endocrine therapy in breast cancer as a strategy for musculoskeletal symptoms, tolerance, and adherence.
Authors
Albina Kibirova
University of West Virginia, Section of Hematology Oncology, Morgantown, WV
Albina Kibirova, Samantha Hall, Abdul Miah, Mohamad Adham Salkeni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Advance Care Planning; Caregiver Support; Coordination and Continuity of Care; End-of-Life Care; Models of Care; Survivorship; and Symptom Biology, Assessment and Management
Track
Advance Care Planning,End-of-Life Care,Survivorship,Coordination and Continuity of Care,Symptom Biology, Assessment, and Management,Models of Care,Caregiver Support
Sub Track
Symptom Biology, Assessment, and Management
Citation
J Clin Oncol 36, 2018 (suppl 34; abstr 192)
DOI
10.1200/JCO.2018.36.34_suppl.192
Abstract #
192
Poster Bd #
E10
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Tamoxifen versus aromatase inhibitors for the adjuvant treatment of breast cancer in older women: A feasibility study to examine differences in cognitive outcomes.
First Author: Emily Anne Underwood
Poster
2012 Breast Cancer Symposium
Vascular toxicities of endocrine therapy in early-stage breast cancer: Encouraging observations in a nontrial setting.
First Author: Susan Dent
Poster
2022 ASCO Annual Meeting
Aromatase inhibitors for breast cancer therapy: Analysis of real-world FAERS data.
First Author: Dawood Findakly
Poster
2022 ASCO Annual Meeting
A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA).
First Author: Ryan Tooker